Skip to main content

Table 1 clinical characteristics of HBs associated to prognoses

From: Analysis of factors related to recurrence of paediatric hepatoblastoma - a single Centre retrospective study

Variables

 

Results

3-year RFS Rate

P

Age (median, months)

 

46.5 (26,71.5)

  

≥54 months (n, %)

YES

37(66)

63.9%

0.007

 

No

19(34)

25%

 

PRETEXT (n, %)

   

0.089

 

I

0

0

 
 

II

26(46)

65.4%

 
 

III

26(46)

38.5%

 
 

IV

4(8)

25%

 

SIOPEL risk stratification (n, %)

   

0.239

 

SR

27(48)

59.9%

 
 

HR

29(52)

40.1%

 

Tumor size (median, cm2)

 

100.84 (69.76,142.31)

  

Initial serum AFP (median, ng/ml)

 

31,125 (5434,74,250)

  

Non-recurrent (n)

 

28

  

Recurrent (n)

 

28

  

Site of tumour recurrence (n, %)

Local

21(75)

  
 

Lung metastasis

7(25)

  

Prognoses (n, %)

Survive

46(82)

  
 

Death

7(13)

  
 

Lost to follow up

3(5)

  

follow-up time (median, months)

 

44

  
  1. “Tumor size” -two major vertical diameters product; “PRETEXT”- Pretreatment extension stage; “AFP”- alpha-fetoprotein; “SR”- standard risk; “HR”- high risk; “RFS”- recurrence free survival